Bi
BioNova Pharma
Shanghai CNFounded 201940 employees
Private CapbiotechPrivateOncology
Platform: BN-101 CNS
Market Cap
N/A
All Drugs
4
Clinical Trials
5
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Lisolemzoparlimab | BIO-7918 | Phase 1 | 1 | TNFα | MM | ||
| BIO-9035 | BIO-9035 | Phase 2/3 | 1 | MDM2 | PVOCD | ||
| Polalemzoparlimab | BIO-1304 | Phase 1/2 | 1 | SMN2 | PsAHemophilia A | ||
| BIO-6952 | BIO-6952 | NDA/BLA | 2 | KRASG12D | FTDTTR Amyloidosis |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)